These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 16239355)
1. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans. Casner PR J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355 [TBL] [Abstract][Full Text] [Related]
2. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. Sosa-Macías M; Elizondo G; Flores-Pérez C; Flores-Pérez J; Bradley-Alvarez F; Alanis-Bañuelos RE; Lares-Asseff I J Clin Pharmacol; 2006 May; 46(5):527-36. PubMed ID: 16638736 [TBL] [Abstract][Full Text] [Related]
3. CYP2D6 polymorphism in a Mexican American population. Mendoza R; Wan YJ; Poland RE; Smith M; Zheng Y; Berman N; Lin KM Clin Pharmacol Ther; 2001 Dec; 70(6):552-60. PubMed ID: 11753272 [TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos. Sosa-Macías M; Dorado P; Alanis-Bañuelos RE; Llerena A; Lares-Asseff I Pharmacology; 2010; 86(1):30-6. PubMed ID: 20588073 [TBL] [Abstract][Full Text] [Related]
5. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis. Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385 [TBL] [Abstract][Full Text] [Related]
6. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700 [TBL] [Abstract][Full Text] [Related]
9. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042 [TBL] [Abstract][Full Text] [Related]
10. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers. Zimmermann T; Schlenk R; Pfaff G; Lach P; Wildfeuer A Arzneimittelforschung; 1995 Jan; 45(1):41-3. PubMed ID: 7893267 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population. Nagai N; Kawakubo T; Kaneko F; Ishii M; Shinohara R; Saito Y; Shimamura H; Ohnishi A; Ogata H Biopharm Drug Dispos; 1996 Jul; 17(5):421-33. PubMed ID: 8830977 [TBL] [Abstract][Full Text] [Related]
12. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830 [TBL] [Abstract][Full Text] [Related]
13. Nicotine metabolism and CYP2D6 phenotype in smokers. Caporaso NE; Lerman C; Audrain J; Boyd NR; Main D; Issaq HJ; Utermahlan B; Falk RT; Shields P Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):261-3. PubMed ID: 11303596 [TBL] [Abstract][Full Text] [Related]
14. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134 [TBL] [Abstract][Full Text] [Related]
15. Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. Dickinson GL; Rezaee S; Proctor NJ; Lennard MS; Tucker GT; Rostami-Hodjegan A J Clin Pharmacol; 2007 Feb; 47(2):175-86. PubMed ID: 17244768 [TBL] [Abstract][Full Text] [Related]
16. [Correlation of genetic polymorphism of cytochrome P4502D6 with dextromethorphan oxidative metabolism in Chinese]. Cai W; Chen B; Tao X; Ling S; Zhang Y Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Jun; 17(3):181-4. PubMed ID: 10837520 [TBL] [Abstract][Full Text] [Related]
17. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152 [TBL] [Abstract][Full Text] [Related]
18. Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity. Ishiguro A; Kubota T; Ishikawa H; Iga T Clin Chim Acta; 2004 Jun; 344(1-2):201-4. PubMed ID: 15149890 [TBL] [Abstract][Full Text] [Related]
19. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. López M; Guerrero J; Jung-Cook H; Alonso ME Eur J Clin Pharmacol; 2005 Nov; 61(10):749-54. PubMed ID: 16249913 [TBL] [Abstract][Full Text] [Related]
20. Identification of CYP2D6 impaired functional alleles in Mexican Americans. Luo HR; Gaedigk A; Aloumanis V; Wan YJ Eur J Clin Pharmacol; 2005 Dec; 61(11):797-802. PubMed ID: 16283274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]